Bloomberg Anywhere Remote Login Bloomberg Terminal Request a Demo

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $58.20 USD
Change Today -0.55 / -0.94%
Volume 1.1M
BMY On Other Exchanges
Symbol
Exchange
New York
Mexico
Sao Paulo
Frankfurt
As of 10:27 AM 09/4/15 All times are local (Market data is delayed by at least 15 minutes).

bristol-myers squibb co (BMY) Snapshot

Open
$58.08
Previous Close
$58.75
Day High
$58.48
Day Low
$57.90
52 Week High
07/20/15 - $70.54
52 Week Low
10/15/14 - $47.55
Market Cap
97.1B
Average Volume 10 Days
8.4M
EPS TTM
$1.67
Shares Outstanding
1.7B
EX-Date
07/1/15
P/E TM
34.8x
Dividend
$1.48
Dividend Yield
2.52%
Current Stock Chart for BRISTOL-MYERS SQUIBB CO (BMY)

bristol-myers squibb co (BMY) Details

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It provides chemically-synthesized drugs or small molecules, and biologics in various therapeutic areas, including virology comprising human immunodeficiency virus infection (HIV); oncology; neuroscience; immunoscience; and cardiovascular. The company’s products include Baraclude for the treatment of chronic hepatitis B virus infection; Daklinza for the treatment of hepatitis C virus infection; Reyataz and Sustiva for the treatment of HIV; Erbitux, an IgG1 monoclonal antibody that targets and blocks the epidermal growth factor receptor; and Sprycel, a multi-targeted tyrosine kinase inhibitor for the treatment of adults with Philadelphia chromosome-positive chronic myeloid leukemia. Its products also comprise Yervoy, a monoclonal antibody for the treatment of patients with metastatic melanoma; Abilify, an antipsychotic agent for adult patients with schizophrenia, bipolar mania disorder, and major depressive disorder; Orencia for use in treating patients with moderately to severely active rheumatoid arthritis; and Eliquis, an oral factor Xa inhibitor targeted at stroke prevention in atrial fibrillation, and the prevention and treatment of venous thromboembolic disorders. In addition, it is developing Opdivo, a human monoclonal antibody, which is in Phase III trials for non-small cell lung cancer, renal cell cancer, and melanoma; Beclabuvir, a non-nucleoside NS5B inhibitor that is in Phase III development for the treatment of HCV; Elotuzumab, a humanized monoclonal antibody, which is in Phase III trials for the treatment of multiple myeloma; and BMS-663068, an investigational compound that is being studied in HIV-1. The company was formerly known as Bristol-Myers Company and changed its name to Bristol-Myers Squibb Company in 1989. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in New York, New York.

25,000 Employees
Last Reported Date: 02/13/15
Founded in 1887

bristol-myers squibb co (BMY) Top Compensated Officers

Chief Executive Officer and Director
Total Annual Compensation: $916.0K
Chief Financial Officer and Executive Vice Pr...
Total Annual Compensation: $910.5K
Chief Scientific Officer, Executive Vice Pres...
Total Annual Compensation: $875.0K
Executive Vice President, General Counsel and...
Total Annual Compensation: $849.8K
Compensation as of Fiscal Year 2014.

bristol-myers squibb co (BMY) Key Developments

Bristol-Myers Squibb Company to Present New Data from its Immuno-Oncology Clinical Development Programs

Bristol-Myers Squibb Company announced that new data from its Immuno-Oncology clinical development programs to be presented at the 16thWorld Conference on Lung Cancer in Denver, CO from September 6 to 9. The company is presenting Opdivo (nivolumab)data in a broad set of patients with lung cancer, across histologies and treatment settings. These data add to the growing body of evidence that may help the scientific community advance their understanding Opdivo’s role in the treatment of lung cancer as a single agent and its potential in combination with Yervoy (ipilimumab).

Bristol-Myers Squibb Company and QIMR Berghofer Medical Research Institute sign Worldwide Collaboration to Discover Novel Immuno-Oncology Antibodies

Bristol-Myers Squibb Company and QIMR Berghofer Medical Research Institute have signed a research collaboration and license agreement to discover novel therapeutic antibodies against an undisclosed immuno-oncology (I-O) target. QIMR Berghofer Medical Research Institute is a translational research institute focused on cancer, infectious diseases, mental health and a range of complex disorders. Bristol-Myers Squibb will be solely responsible for clinical development and commercialization of antibodies discovered through the collaboration.

Bristol-Myers Squibb Promotes Betty Edery to the Post of General Counsel for France

Bristol-Myers Squibb has promoted Betty Edery to the post of general counsel for France, just over a year after making its last local head of legal appointment. Edery, who was formerly senior legal counsel for Bristol-Myers Squibb France, takes over from Alexandra de Rambuteau as general counsel and a member of the executive committee. De Rambuteau was appointed as general counsel in June last year. It is not known why she is leaving the company or where her next destination is. Edery joined Bristol-Myers Squibb in January 2013, having previously worked for Hogan Lovells in Paris for seven years as a corporate and regulatory lawyer specialising in the pharmaceutical sector.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BMY:US $58.16 USD -0.59

BMY Competitors

Market data is delayed at least 15 minutes.

Company Last Change
AbbVie Inc $60.20 USD -1.38
Allergan plc $298.75 USD +1.31
Eli Lilly & Co $80.83 USD -0.77
Medtronic PLC $68.69 USD -1.29
Novo Nordisk A/S kr365.00 DKK -8.40
View Industry Companies
 

Industry Analysis

BMY

Industry Average

Valuation BMY Industry Range
Price/Earnings 55.8x
Price/Sales 6.1x
Price/Book 6.6x
Price/Cash Flow 55.5x
TEV/Sales 5.3x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BRISTOL-MYERS SQUIBB CO, please visit www.bms.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.